{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-018575","form_type":"8-K","ticker":"HEPA","cik":"0001583771","company_name":"Hepion Pharmaceuticals, Inc.","filed_at":"2026-04-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.519729+00:00","generated_at":"2026-05-15T04:53:51.320970+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Hepion Pharmaceuticals raises $700,000 in private placement of 17.5 million shares","bullets":["Hepion entered securities purchase agreements with accredited investors on April 21, 2026, selling 17,500,000 shares at $0.04 per share.","Gross proceeds from the private placement were $700,000, and the offering closed on the same date.","The shares were issued in reliance on exemptions under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D.","Gary Stetz, Interim CEO, signed the 8-K filing on behalf of Hepion Pharmaceuticals."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-018575","json":"https://secwatch.observer/filing/0001493152-26-018575.json","markdown":"https://secwatch.observer/filing/0001493152-26-018575.md","text":"https://secwatch.observer/filing/0001493152-26-018575.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583771/000149315226018575/0001493152-26-018575-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583771/000149315226018575/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-15T04:53:51.320970+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fa0e571b695c08ceeffc723e6e8c207f7471ac16","claim":"Hepion Pharmaceuticals, Inc. issued 17,500,000 shares of common stock of common stock to certain accredited investors for $0.04 per share for gross proceeds of $700,000.","evidence_excerpt":"On April 21, 2026, Hepion Pharmaceuticals, Inc. (the “Company”) entered into securities purchase agreements (the “Agreements”) with certain accredited investors (the “Investors”) pursuant to which the Company agreed to sell and issue to the Investors in a private placement offering (the “Offering”), an aggregate offering of 17,500,000 shares of common stock, par value $0.0001 per share (the “Common Stock”) at an offering price of $0.04 per share for gross proceeds of $700,000.","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583771/000149315226018575/0001493152-26-018575-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"common stock"},{"label":"Shares","value":"17,500,000 shares of common stock"},{"label":"Purchaser","value":"certain accredited investors"},{"label":"Consideration","value":"$0.04 per share for gross proceeds of $700,000"}],"fact_type":"equity_issuance"},{"claim_id":"bb8648e8ef8670a5797275d5531ca4b2cd27276a","claim":"Hepion Pharmaceuticals, Inc. entered into securities purchase agreements with certain accredited investors valued at $700,000 (effective 2026-04-21).","evidence_excerpt":"On April 21, 2026, Hepion Pharmaceuticals, Inc. (the “Company”) entered into securities purchase agreements (the “Agreements”) with certain accredited investors (the “Investors”) pursuant to which the Company agreed to sell and issue to the Investors in a private placement offering (the “Offering”), an aggregate offering of 17,500,000 shares of common stock, par value $0.0001 per share (the “Common Stock”) at an offering price of $0.04 per share for gross proceeds of $700,000.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583771/000149315226018575/0001493152-26-018575-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain accredited investors"},{"label":"Value","value":"$700,000"},{"label":"Effective","value":"2026-04-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}